Escherichia coli strain Nissle 1917-from bench to bedside and back: History of a special Escherichia coli strain with probiotic properties

FEMS Microbiology Letters

Volumn 363, Issue 19, 2016, Pages

  Sonnenborn, Ulrich ^a  

^a Ardeypharm GmbH   (Germany)

Author keywords

Discovery; E. coli Nissle 1917; Escherichia coli; History; Probiotic

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; DRUG MECHANISM; ESCHERICHIA COLI; FUNGICIDAL ACTIVITY; GROWTH INHIBITION; HISTORY OF MEDICINE; HUMAN; MEDICAL RESEARCH; NONHUMAN; ORGANISMAL INTERACTION; PRIORITY JOURNAL; SHORT SURVEY; ANTIBIOSIS; ART; GASTROINTESTINAL TRACT; GERMANY; HISTORY; INTESTINE FLORA; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; TRANSLATIONAL RESEARCH;

ANTIBIOSIS; ESCHERICHIA COLI; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GERMANY; HISTORY, 20TH CENTURY; HUMANS; PROBIOTICS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84992188321     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1093/femsle/fnw212     Document Type: Short Survey

References (42)

1. Altenhoefer A, Oswald S, Sonnenborn U et al. The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Mic 2004;1660: 1-7.
2. Baquero F, Moreno F. The microcins. FEMS Microbiol Lett 1984;23:117-24.
3. Behnsen J, Deriu E, Sassone-Corsi M et al. Probiotics: properties, examples and specific applications. Cold Spring Harb Perspect Med 2013:3:a010074.
4. Blevinsz SM, BronzeMS. Robert Koch and the 'golden age' of bacteriology. Int J Infect Dis 2010;14:e744-51.
5. Blum-Oehler G, Oswald S, Eiteljörge K et al. Development of strain-specific DNA reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol 2003;154:59-66.
6. De Lorenzo V, Aguilar A. Antibiotics from gram-negative bacteria: do they play a role in microbial ecology? Trends Biochem Sci 1984;9:266-9.
7. Deriu E, Liu JZ, Pezeshki M et al. Probiotic bacteria reduce Salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe 2013;14:26-37.
8. Escherich T. Die Darmbakterien des Saüglings und ihre Beziehung zur Physiologie der Verdauung. Stuttgart: Ferdinand Enke, 1886.
9. EDQM (European Directorate for the Quality of Medicines & HealthCare). Annual Report 2014. Strasbourg: Council of Europe, April 2015.
10. FAO/WHO. Probiotics in Food. Health and Nutritional Properties and Guidelines for Evaluation. FAO Food and Nutrition Paper 85. Rome: Food and Agricultural Organization, 2006.
11. Fredericq P. Colicins. Annu Rev Microbiol 1957;11:7-22.
12. Fric P. Probiotics and prebiotics-renaissance of a therapeutic principle. Open Med 2007;2:237-70.
13. Geisse A. Behandlung infektiöser Darmerkrankungen mit "Mutaflor". Ther d Gegenwart 1919;60:90-3.
14. Gratia A. Sur un remarquable exemple d'antagonisme entre deux souches de colibacille. CR Soc Biol 1925;93:1040-2.
15. Hawkey PM. Action against antibiotic resistance: no time to lose. Lancet 1998;351:1298-9.
16. Henker J, Laass MW, Blokhin BM et al. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 2007;166:311-8.
17. Irrgang K, Sonnenborn U. The Historical Development of Mutaflor Therapy. Herdecke: Ardeypharm GmbH, 1988.
18. Jacobi CA, Malfertheiner P. Escherichia coli Nissle 1917 (Mutaflor): new insights into an old probiotic bacterium. Digest Dis 2011;29:600-7.
19. Lodinova-Zadnikova R, Sonnenborn U. Effect of preventive administration of a non-pathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 1997;71:224-32.
20. Loew D. Leben und Werk von Alfred Nissle. In: Alfred-Nissle-Gesellschaft e.V., (ed.). Symposiumsband 4. Interdisziplin äres Symposium Darmflora in Symbiose und Pathogenit ät-Mikrobiologische Grundlagen und klinische Anwendung von Escherichia coli Stamm Nissle 1917. Hagen, 2001, 11-9.
21. Maloy S, Schaechter M. The era of microbiology: a Golden Phoenix. Int Microbiol 2006;9:1-7.
22. Metchnikoff E. The Prolongation of Life. London: Heinemann, 1907.
23. Nissle A. Über die Grundlagen einer neuen ursächlichen Bekämpfung der pathologischen Darmflora. Deut Med Wochenschr 1916;42:1181-4.
24. Nissle A. Die antagonistische Behandlung chronischer Darmstörungen mit Colibakterien. Med Klin 1918;2:29-33.
25. Nissle A. Weiteres über Grundlagen und Praxis der Mutaflorbehandlung. Deut Med Wochenschr 1925;44:1809-13.
26. Nissle A. Zur Theorie und Praxis der Mutaflortherapie. Hippokrates 1948;19:31-8.
27. Oelschlaeger TA. Mechanisms of probiotic actions-a review. Int J Med Microbiol 2010;300:57-62.
28. Patzer SI, Baquero MR, Bravo D et al. The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 2003;149:2557-70.
29. Reister M, Hoffmeier K, Krezdorn N et al. Complete genome sequence of the Gram-negative probiotic Escherichia coli strain Nissle 1917. J Biotechnol 2014;187:106-7.
30. Rörig F. Weiteres über Mutaflor bei Koliinfektion der Harnwege. München Med Wschr 1921;31:980-1.
31. Sartor RB. Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroen 2005;21:44-50.
32. Sassone-Corsi M, Raffatellu M. No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J Immunol 2015;194:4081-7.
33. Scaldaferri F, Gerardi V, Mangiola F et al. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. World J Gastroentero 2016;22:5505-11.
34. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1012-8.
35. Sonnenborn U, Schulze J. The non-pathogenic Escherichia coli strain Nissle 1917-features of a versatile probiotic. Microb Ecol Health Dis 2009;21:122-58.
36. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207-14.
37. Ukena SN, Singh A, Dringenberg U et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2:e1308.
38. Ulrich P. Klinische Beobachtungen überMutaflor bei verschiedenen Erkrankungen. Med Klin 1926;30:1152-3.
39. Von Bünau R, Jaekel L, Schubotz E et al. Escherichia coli strain Nissle 1917: significant reduction of neonatal calf diarrhea. J Dairy Sci 2005;88:317-23.
40. Wehkamp J, Harder J, Wehkamp K et al. NF-κB-and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72: 5750-8.
41. Werlé W. Beitrag zur Therapie postdysenterischer Darmstörungen. München Med Wschr 1921;49:1581-2.
42. Zyrek AA, Cichon C, Helms S et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKC? redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007;9: 804-16.